VectorPoint’s cohesive team of Managing Directors, Operating Partners, Advisors,  and other Investment Professionals can make decisions quickly while preserving the integrity and timeliness of the advising and investment process.  Our team brings a successful track record in investing in in venture capital, private equity, target sector and industry operational experience to bear to assist portfolio companies, boards of directors and their management teams as they navigate through business challenges.  This experience is key as we work to assist advisory clients and portfolio companies, boards of directors and their management teams navigate through business challenges.

The VectorPoint team consists of individuals with a broad array of backgrounds and experiences in management, finance, consulting, manufacturing, accounting and technology.  Together we provide patient and dedicated support to management teams to help take their companies to the next level.


Don is co-founder of VectorPoint Ventures were he currently brings his extensive experience in early stage and growth stage investing, portfolio company management, entrepreneurship and finance to bear.  He has over 25 years of experience in board, finance and operational roles in a variety of industries and disciplines.  In his career he has served in several operational and leadership functions, including business development, finance, information technology, strategic planning and implementation, investment banking, and corporate development.   He has founded or co-founded several ventures and has held key management positions in several small and middle market companies, including serving as VP Finance, CFO, COO and board director positions in both private and public companies.



David Starr has extensive management and leadership experience in life sciences and consumer products spanning all facets of operations and company stages – from company formation through explosive growth. His experience includes product definition, market research and analysis, distribution planning, sales management, product and technical support, manufacturing planning, financial operations, HR, engineering management, intellectual property and patent strategy, quality and regulatory management, fund raising, business development, clinical study design, medical education, healthcare economics and reimbursement.
Mr. Starr has spent the past 25 years in the medical device sector with an eye towards developing affordable, and easy to use medical technology that address today’s critical needs and what it takes to achieve commercial success. He is adept at working with clinicians in a variety of specialties to focus efforts on what is clinical actionable, “doable” from an engineering perspective and address large markets with clear unmet needs. These clinical areas include, emergency medicine, trauma, cardiology, radiology, anesthesiology, nursing, primary care, and first responders. Mr. Starr has raised over $50 million of investor money from angels, corporations, and venture capital firms including several overseas VC’s.



Jolene Anderson brings extensive experience in advising, mentoring and connecting early stage and growth stage companies with the strategic advice and resources required to scale their product or service. She has provided investor and media relations, executive coaching and has significant experience in providing advice for alternative financing, exit strategy and access to grant funding. Ms. Anderson has over 25 years’ experience in advising companies, in the Pacific Rim and North America. Her career experience includes senior development strategist for various private companies and investor relations for a public company, focused on STEM education. She is a previous advisor for Kineta Bio, a life science company based in Seattle, WA. Ms. Anderson currently serves as Chapter President of the Boise, ID Keiretsu Forum, and has served on the Life Science Deal Screening Committee for Keiretsu Forum NW for the past 5 years. She is a member of the Idaho Technology Council and has participated as a mentor for various life science companies and technology companies and food companies in WA, ID and UT. Ms. Anderson has been an active mentor, participating in the Microsoft Airband Initiative, worked with the Venture Deal Forum in UT and ID, active volunteer for the SBIR/STTR events held at Boise State University, and served as a committee chair for the past 3 years for WeRoc, Women Accessing Capital, a presentation of, held in Salt Lake City, Utah. In 2018, Ms. Anderson was given the Excellence in Finance Award by the Idaho Business Review. Ms. Anderson currently serves on the Board of the St. Alphonsus Hospital Foundation in Idaho.



Dr. Molly H. Shor supports two angel investment groups – E8 Angels and Keiretsu Forum Northwest – on deal flow, deal review, due diligence and outreach to entrepreneurs. As a Senior Fellow for E8, a clean technology angel investment group, Dr. Shor supervises PhD and post-doctoral fellows who assist in deal flow screening and due diligence. She also serves on and leads some due diligence teams. Dr. Shor has made angel investments in clean-technology deals. As Impact Committee Chair for Keiretsu Forum Northwest, Dr. Shor runs committee deal review meetings, and recruits and screens deal flow. Dr. Shor serves as program chair for the annual Keiretsu/E8 co-hosted Impact Forum – organizing speakers, recruiting suitable companies to apply, and supporting the screening process. Dr. Shor served as Keiretsu’ s technical due diligence team lead for one deal. She enjoys coaching entrepreneurs and the deal screening process. Dr. Shor regularly attends the Clean Technology Alliance breakfast forums and tracks the clean technology landscape.

Prior to joining E8 Angels and Keiretsu Forum Northwest, Dr. Shor served at Oregon State University’s School of Electrical Engineering and Computer Science as a regular and research faculty member for over a decade and in a program administration role for several years. She served as principal investigator on eight grants, supervised graduate research, published research papers, taught graduate-level and senior-level coursework, and served on and chaired committees for her professional societies, including award and membership committees. She served as finance chair for multiple international conferences for the IEEE Control Systems Society, and as workshop chair and as program co-chair for conferences and workshops.



Duffy has 40 years of experience in the life science industry. This experience includes positions in medical device, pharmaceutical and biotechnology firms. Early in his career he worked in a variety of strategy, finance, marketing and general management roles, both domestic and international, for Baxter Laboratories. Duffy subsequently became the Managing Director for the Canadian subsidiary of Boots Pharmaceutical. In the past 25-30 years, he has served as President or CEO for a number of biotech and medical device firms, primarily based in the New England area. These firms include ConjuChem, Inc., Anika Therapeutics, Zelos Therapeutics, Pacgen, and Ischemix Inc. Duffy has raised ~$250 million in equity for the companies he has run, encompassing investments from public offerings, venture capital investors and angel investors. He has IPO’ed two companies and has negotiated a number of partnering/licensing agreements. He has overseen the successful preclinical and clinical development of many biopharmaceuticals and medical devices in a variety of therapeutic areas.



Ken Vaughn is the Director of Impact Investments for VertueLab, Oregon’s cleantech Signature Research Center that catalyzes the development of new technologies to reverse climate change and build a new green economy. He manages the program that provides grants to university researchers and makes investments in cleantech startup companies. The program is designed to accelerate research and technology development, remove barriers to customer adoption, and catalyze follow-on investments by private investors. He collaborates with innovators, entrepreneurs, investors, mentors, support organizations, and senior management talent to help assemble the elements necessary for launching successful businesses in the cleantech sector.

Mr. Vaughn is an accomplished professional with broad experience spanning executive management, engineering, marketing, strategic planning, product development, operations, economic development, and early-stage Investing. He has experience in nonprofits, entrepreneurial companies, and multi-national corporations in leadership, staff roles, and line roles.



Mark Neuhausen is a technologist who has extensive management and leadership experience, in roles ranging from small companies to running a $200M annual business. In these roles, he frequently acted as an entrepreneur, conceiving and launching new products and services. Since 2015 Mr. Neuhausen, as an angel investor, has mentored and advised entrepreneurs and startups while investing in over 20 early-to-mid stage companies. He is a problem solver, whether the problems are technical, business, or some combination of the two.
Mr. Neuhausen’s first career was in defense electronics, where he was a systems engineer for the world’s first heterogeneous local area network (IEEE 802.3), chief project engineer for a signals intelligence system on the U-2 aircraft, and vice president at Raytheon for remote reconnaissance systems that included ground control stations for the USAF’s first unmanned aerial vehicle (UAV) and for remotely piloted vehicles (RPVs). In 1999 Mr. Neuhausen moved to his second career, networking which morphed into information technology. He held various positions including technical lead for the US business arm of an Accenture venture company; CTO for managed services at SAIC, Inc.; technical leader/distinguished services engineer/director at Cisco Systems, and account chief technologist at Hewlett Packard Enterprise (HPE). At HPE he was responsible for pre-sales and selling strategy for Microsoft, HPE’s largest customer. Joint projects including defining phase 2 for a submersible unattended data center.



Larry has over 35 years of experience as a CFO and consultant working with early and growth stage companies. He works with clean technology companies and other technology industry enterprises. He has worked with a wide range of venture capital and angel investor backed companies. Many of the companies he has supported have been on multiple fastest-growing companies lists, best places to work for lists, and/or awarded a Most Admired company listing. Larry was the managing member for three Angel Oregon investors groups. Larry was a judge and mentor for Cleantech Open competitions and speaks and advises for the Cascadia Cleantech Accelerator. He founded Willeman Strategy Partners Inc in 2002.



Rick has more than thirty years’ experience as a successful entrepreneur, company creator, active lead investor and venture capitalist.  Rick is a co-founder of and advisor to VectorPoint Ventures.  Rick is also currently Founder and President of Pillar Management, an Oregon based group of seasoned professional investors and entrepreneurs who have made active investments in over fifty companies primarily based in the Northwest.  Pillar Management has been responsible for raising over $130 million and assists its portfolio companies through operations, strategic planning, developing management teams, serving on boards and advisory boards, strategic alliances and capital expansion.  He has been involved in successful initial public stock offerings and mergers and acquisitions, resulting in many positive liquidity events.

Rick is a co-founder and former Director of Metro One Telecommunications, an Oregon based NASDAQ Company.  Rick was instrumental in helping the company grow from a start-up to a nationwide company with revenues approaching $300 million.  He helped pioneer enhanced directory assistance which served two thirds of the US population, employing over 7,000 people as 31 branch locations throughout the United States.   During Rick’s involvement with the company, Metro One achieved a market capitalization of well over $1 billion and provided exceptional returns to its investors.  Metro One was named one of the most outstanding and fastest growing companies by both Forbes and Fortune Magazine.



Greg has over 30 years of global consumer brand experience that includes over a decade as CEO/President/Board/Founder/Chairman. His experience ranges from Fortune 500 companies to start ups. Greg consistently finds and executes strategic paths to successful company and brand performance. He has won numerous major awards for his ability to create, grow, and turnaround companies in fast pace industries that include footwear/apparel, cosmetics, personal care, and household products. Industry awards include: Fragrance of The Year, Footwear Brand of the Year, and Finalist NW Startup of the Year.

As a talented and seasoned senior executive with Colgate-Palmolive and Unilever he was responsible for successfully building and turning around billion dollar global brands such as Colgate Dental Care, Palmolive Brands, Vaseline and Ponds Skin Care. As a CEO/President and Board Member for leading footwear companies Greg brought his expertise to build wholesale and retail teams to grow leading brands such as Dr. Marten’s, Florsheim, and Naturalizer. His start-up experience includes creating a footwear company to save women’s feet from the damage caused by high heels, Oh! Shoes, Inc.



David Eastman has over 35 years of executive management, product marketing and management, operations, strategic marketing, start-up venture development and new product launch experience marketing life science, high technology, and telecom products.

Mr. Eastman currently is the Chief Executive Officer of Gamma Therapeutics, an Oregon early stage biotechnology venture developing medical devices for cardiovascular disease risk assessment, surgical therapy and combat casualty care based upon the use of human clotting proteins.

Prior to Gamma Therapeutics, Mr. Eastman was the interim CEO of Yecuris, a biotechnology venture developing humanized mouse models for use in Life Science drug discovery. Mr. Eastman developed the business model for Yecuris, raised $3.0 M in venture capital and angel funding and developed strategic partnerships with five of the world’s leading pharmaceutical companies–AstraZeneca, Merck, Pfizer, GlaxoSmithKline and Roche–and two of the world’s leading cell suppliers, Lonza & BD Biologicals. Mr. Eastman sits on the Board of Directors of four Life Science start-ups including NeuraMedica, OmnEcoil, Sympano and MagnetoOrganics. In his role as an OTRADI Business Incubator biomentor, Mr. Eastman is currently mentoring several OBI start-ups in winning NIH/NSF multi-million dollar grants including Caregiven, Veana Therapeutics and Motusi.